A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)
Incyte Corporation
426 participants
Sep 8, 2026
INTERVENTIONAL
Conditions
Summary
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered intravenous (IV) in accordance with the protocol-defined requirements.
Best Available Therapy (BAT) will be selected by the investigator.
Locations(175)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07623200